Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Tewes Tralau & Andreas Luch. (2013) The evolution of our understanding of endo-xenobiotic crosstalk and cytochrome P450 regulation and the therapeutic implications. Expert Opinion on Drug Metabolism & Toxicology 9:12, pages 1541-1554.
Read now
Read now
Tewes Tralau & Andreas Luch. (2012) “Drugs on oxygen”: an update and perspective on the role of cytochrome P450 testing in pharmacology. Expert Opinion on Drug Metabolism & Toxicology 8:11, pages 1357-1362.
Read now
Read now
Articles from other publishers (15)
Xin Lv, Zhe Wang, Zhen Wang, Hang Yin, Yangliu Xia, Lili Jiang & Yong Liu. (2023) Drug-drug interaction potentials of tucatinib inhibition of human UDP-glucuronosyltransferases. Chemico-Biological Interactions 381, pages 110574.
Crossref
Crossref
Xin Lv, Zhe Wang, Zhen Wang, Hang Yin, Yangliu Xia, Lili Jiang & Yong Liu. (2023) Inhibition of human UDP-glucuronosyltransferase enzyme by ripretinib: Implications for drug-drug interactions. Toxicology and Applied Pharmacology 466, pages 116490.
Crossref
Crossref
Claire Steinbronn, Xinning Yang, Jingjing Yu, Hristina Dimova, Shiew‐Mei Huang, Isabelle Ragueneau‐Majlessi & Nina Isoherranen. (2021)
Do Inhibitory Metabolites Impact DDI Risk Assessment? Analysis of
in vitro
and
in vivo
Data from NDA Reviews Between 2013 and 2018
. Clinical Pharmacology & Therapeutics 110:2, pages 452-463.
Crossref
Crossref
Jukka Hakkola, Janne Hukkanen, Miia Turpeinen & Olavi Pelkonen. (2020) Inhibition and induction of CYP enzymes in humans: an update. Archives of Toxicology 94:11, pages 3671-3722.
Crossref
Crossref
Nina Isoherranen & Robert S. Foti. 2020. Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters. Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters
273
309
.
Jill C. Chappell, P. Kellie Turner, Y. Anne Pak, James Bacon, Alan Y. Chiang, Jane Royalty, Stephen D. Hall, Palaniappan Kulanthaivel & Joseph V. Bonventre. (2018) Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clinical Pharmacology & Therapeutics 105:5, pages 1187-1195.
Crossref
Crossref
Kenta Yoshida, Kazuya Maeda, Akihiko Konagaya & Hiroyuki Kusuhara. (2018) Accurate Estimation of In Vivo Inhibition Constants of Inhibitors and Fraction Metabolized of Substrates with Physiologically Based Pharmacokinetic Drug–Drug Interaction Models Incorporating Parent Drugs and Metabolites of Substrates with Cluster Newton Method. Drug Metabolism and Disposition 46:11, pages 1805-1816.
Crossref
Crossref
Jing Jing, Cara Nelson, Jisun Paik, Yoshiyuki Shirasaka, John K. Amory & Nina Isoherranen. (2017)
Physiologically Based Pharmacokinetic Model of All-
trans
-Retinoic Acid with Application to Cancer Populations and Drug Interactions
. Journal of Pharmacology and Experimental Therapeutics 361:2, pages 246-258.
Crossref
Crossref
Ken Grime, Rikard Pehrson, Pär Nordell, Michael Gillen, Wolfgang Kühn, Timothy Mant, Marie Brännström, Petter Svanberg, Barry Jones & Clive Brealey. (2016)
An S‐warfarin and AZD1981 interaction:
in vitro
and clinical pilot data suggest the N‐deacetylated amino acid metabolite as the primary perpetrator
. British Journal of Clinical Pharmacology 83:2, pages 381-392.
Crossref
Crossref
Jennifer E. Sager, Sasmita Tripathy, Lauren S.L. Price, Abhinav Nath, Justine Chang, Alyssa Stephenson-Famy & Nina Isoherranen. (2017) In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation. Biochemical Pharmacology 123, pages 85-96.
Crossref
Crossref
Manisha Bhateria, Rachumallu Ramakrishna, Santosh Kumar Puttrevu, Anil K. Saxena & Rabi Sankar Bhatta. (2016) Enantioselective inhibition of Cytochrome P450-mediated drug metabolism by a novel antithrombotic agent, S002-333: Major effect on CYP2B6. Chemico-Biological Interactions 256, pages 257-265.
Crossref
Crossref
Y. Cheng, L. Ma, S.-Y. Chang, W. G. Humphreys & W. Li. (2016) Application of Static Models to Predict Midazolam Clinical Interactions in the Presence of Single or Multiple Hepatitis C Virus Drugs. Drug Metabolism and Disposition 44:8, pages 1372-1380.
Crossref
Crossref
A. R. Masters, B. T. Gufford, J. B. L. Lu, I. F. Metzger, D. R. Jones & Z. Desta. (2016) Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers. Journal of Pharmacology and Experimental Therapeutics 358:2, pages 230-238.
Crossref
Crossref
Bahareh Honarparvar, Thavendran Govender, Glenn E. M. Maguire, Mahmoud E. S. Soliman & Hendrik G. Kruger. (2013) Integrated Approach to Structure-Based Enzymatic Drug Design: Molecular Modeling, Spectroscopy, and Experimental Bioactivity. Chemical Reviews 114:1, pages 493-537.
Crossref
Crossref
Justin D. Lutz, Brooke M. VandenBrink, Katipudi N. Babu, Wendel L. Nelson, Kent L. Kunze & Nina Isoherranen. (2013) Stereoselective Inhibition of CYP2C19 and CYP3A4 by Fluoxetine and Its Metabolite: Implications for Risk Assessment of Multiple Time-Dependent Inhibitor Systems. Drug Metabolism and Disposition 41:12, pages 2056-2065.
Crossref
Crossref